Cell Reports MethodsCancer BiologyPeer-reviewed journal article
Assessing PARP trapping dynamics in ovarian cancer using a CRISPR-engineered FRET biosensor
Daniel MarksiD, Edwin GarcíaiD, Sunil KumariD, Katie TysoniD, Caroline KochiD, Aleksandar P. IvanoviD, Joshua B. EdeliD, Hasan MirzaiD, William FlanaganiD, Christopher W. DunsbyiD, P. M. W. FrenchiD, Iain A. McNeishiD
Abstract
Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionised the treatment of ovarian high grade serous carcinoma (HGSC), especially those with defective homologous recombination. However, the emergence of resistance poses a critical challenge, as over 50% of patients relapse within three years. The mechanisms underlying changes in PARP trapping, a central aspect of PARPi efficacy, are not well understood due to limitations in current experimental methodologies. Existing techniques lack resolution and throughput, impeding efforts to study PARP trapping dynamics over time with single-cell resolution. Effective tools to study PARP trapping in live cells are urgently needed to elucidate resistance mechanisms and inform therapeutic strategies. To address this, we used CRISPR-Cas9 gene editing to dual-label endogenous PARP1 with EGFP and mCherryFP in OVCAR4 cells to develop a novel intramolecular FRET-based biosensor that enables real-time, single-cell visualization of PARP trapping dynamics in live cells. High-content fluorescence lifetime imaging microscopy (FLIM) revealed dose dependent PARP trapping upon exposure to PARP inhibitor and distinguished between the trapping efficiencies of four different PARPi (veliparib, olaparib, rucaparib, talazoparib). Moreover, we found reduced PARP trapping in PARPi-resistant models, both in vitro and in vivo, providing critical evidence for altered PARP trapping as a resistance mechanism and illustrating the potential of this FRET biosensor to interrogate resistance mechanisms quantitatively. This PARP trapping biosensor represents a transformative advance, enabling dynamic, high-resolution analysis of mechanisms underlying cancer drug resistance. It provides critical insights into the heterogeneity of PARPi resistance, with implications for developing more effective therapies and improving personalised treatment strategies for ovarian cancer patients. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=58 SRC="FIGDIR/small/642798v1_ufig1.gif" ALT="Figure 1"> View larger version (11K): org.highwire.dtl.DTLVardef@1c5ee67org.highwire.dtl.DTLVardef@1a6d101org.highwire.dtl.DTLVardef@e3a2bborg.highwire.dtl.DTLVardef@d0ba03_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: fluorescence / live-cell microscopy
- research focus: cell type annotation
- approach: genetic perturbation / CRISPR
- Citations
- 2
- FWCI
- 0.82
- Field percentile
- top 23%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The Treatment of Clear Cell Ovarian Cancer with the Poly(ADP- Ribose) Polymerase (PARP1) Inhibitors (AG14361,Veliparib,Olaparib) as Chemosensitizers.
J. A. de Soto·bioRxiv·Mar 28, 2020
- PARG inhibition induces replication catastrophe in ovarian cancer cells with down-regulated DNA replication genes
C. Coulson-Gilmer, R. Morgan, … S. Taylor·bioRxiv·Jul 13, 2020
- Targeting Wnt Signaling To Overcome PARP Inhibitor Resistance
Tomomi M. Yamamoto, Alexandra McMellen, … Benjamin G. Bitler·bioRxiv·Jul 27, 2018
- Targeting RAD52 overcomes PARP inhibitor resistance in preclinical Brca2-deficient ovarian cancer model
Yukihide Ota, Vijayalaxmi G. Gupta, … Dineo Khabele·bioRxiv·Sep 24, 2025
- Molecular Response to PARP1 Inhibition in Ovarian Cancer Cells as Determined by Mass Spectrometry Based Proteomics
- Generation of a PARPi-sensitive homozygous BRCA1-methylated OVCAR8 cell line using targeted CRISPR gene editing
Ksenija Nesic, Sally Beard, … Matthew J. Wakefield·bioRxiv·Sep 23, 2024